Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pluri Inc PLUR

Healthcare Biotechnology
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical... see more

Recent & Breaking News (NDAQ:PLUR)

The Daily Biotech Pulse: Merrimack Pulls The Plug On Early-Stage Trial, Legal Headache For Novartis-Amgen Migraine Partnership

Benzinga.com  April 5, 2019

Mid-Morning Market Update: Markets Open Higher; Constellation Brands Tops Q4 Estimates

Benzinga.com  April 4, 2019

Pluristem Therapeutics Inc. Announces Pricing of Its Public Offering and Registered Direct Offering for Aggregate Proceeds of Approximately $20 Million

GlobeNewswire April 4, 2019

The Daily Biotech Pulse: Recro Restructures, Biotechs Raise Proceeds In Droves, Silk Road, NGM Biopharma To Debut

Benzinga.com  April 4, 2019

Pluristem Therapeutics Inc. Announces Proposed Public Offering of Common Stock and Warrants and Concurrent Registered Direct Offering of Common Stock

GlobeNewswire April 3, 2019

Pluristem Therapeutics Announces Completion of 2nd Cohort and DSMB Approval to Enroll Final Cohort in Phase I Hematological Study of PLX-R18

GlobeNewswire March 12, 2019

Pluristem Enters into Collaboration with NASA to Study PLX Therapeutic Benefits in Space Missions

GlobeNewswire February 20, 2019

RESTORE Consortium, of which Pluristem is a member, Nominated to Be One of Two Finalists Competing for a Potential Award for Development of Advanced Therapeutics

GlobeNewswire February 11, 2019

Pluristem to Collaborate with Israeli Ministry of Defense in the Treatment of Burn Injuries

GlobeNewswire January 22, 2019

Pluristem Therapeutics Reports Successful Case Study in Treatment of Buerger’s Disease Patient

GlobeNewswire January 9, 2019

Pluristem Concludes Positive Meeting with FDA on Development Plan for Acute Radiation Syndrome

GlobeNewswire January 3, 2019

Pluristem Therapeutics Recaps Key Opinion Leader Meeting on Peripheral Artery Disease (PAD)

GlobeNewswire December 17, 2018

Reminder- Pluristem Therapeutics to Host Key Opinion Leader Meeting on Peripheral Artery Disease Tomorrow

GlobeNewswire December 13, 2018

Pluristem Therapeutics Enters into Cell Thawing Device License Agreement with Chart Industries, Inc.

GlobeNewswire December 4, 2018

Pluristem Presents Data from First Cohort in Ongoing Phase I Hematological Study at the American Society of Hematology (ASH) Annual Meeting

GlobeNewswire December 3, 2018

The Real Impact of PAD - Pluristem Therapeutics to Host Key Opinion Leader Meeting on Peripheral Artery Disease

GlobeNewswire November 29, 2018

Pluristem to Present First Cohort Data from PLX-R18 Hematological Study at American Society of Hematology’s (ASH) Annual Meeting

GlobeNewswire November 28, 2018

Report: Exploring Fundamental Drivers Behind Pluristem Therapeutics, RXi Pharmaceuticals, Saga Communications, Global Self Storage, Sequential Brands Group, and Finjan — New Horizons, Emerging Trends, and Upcoming Developments

GlobeNewswire November 19, 2018

New Findings from Pluristem’s Phase II IC study: PLX-PAD Cells Significantly Improves Blood Glucose Control (HbA1c) and Reduce Chronic Inflammation

GlobeNewswire November 12, 2018

Pluristem Therapeutics Reports Fiscal 2019 First Quarter Results and Provides Corporate Update

GlobeNewswire November 8, 2018